Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Co-Diagnostics adds four new experts to its Scientific Advisory Board

The molecular diagnostics company is welcoming Idaho Technology/BioFire CSO Carl Wittwer, pathology professor Karen Carroll, biotech veteran Noriko Kusukawa and Yale research scientist Anne Wyllie to the board

Co-Diagnostics (NASDAQ:CODX) Inc has beefed up its Scientific Advisory Board with the addition of four new experts.

The molecular diagnostics company is welcoming Idaho Technology/BioFire CSO Carl Wittwer, pathology professor Karen Carroll, biotech veteran Noriko Kusukawa and Yale research scientist Anne Wyllie to the board.

"We are honored to have such talented and renowned industry leaders advising Co-Diagnostics,” CEO Dwight Egan said in a statement.

“We believe that their experience will significantly help guide the company as we continue our trajectory of growth and expansion into new verticals, new markets, and innovative molecular diagnostic solutions."

READ: Co-Diagnostics says its joint venture CoSara receives clearance from Indian regulators from Hepatitis B viral load test

Wittwer is professor emeritus of pathology at the University of Utah who developed rapid-cycle PCR, the capillary LightCycler system, high resolution melting, and extreme PCR.

Carroll is director of the Division of Medical Microbiology at Johns Hopkins University School of Medicine, and a Fellow of the American Academy of Microbiology, the Infectious Diseases Society of America, and the College of American Pathologists.

Kusukawa is a 35-year veteran of biotech and healthcare industries who has authored numerous articles and worked in the United States and Japan directing strategic investments in new technology.

Wyllie is a Research Scientist and Principal Investigator of SalivaDirect at Yale University who is now well-recognized for pushing forward on the use of saliva as a superior sample for creating high-quality, low-cost SARS-CoV-2 testing.

The four new members join Brent Satterfield, Co-Diagnostics co-founder, on the scientific advisory board.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK